1887

Abstract

Dengue is a mosquito-borne disease caused by four related but distinct dengue viruses, DENV-1 to DENV-4. Dengue is endemic in most tropical countries, and over a third of the world's population is at risk of being infected. Although the global burden is high, no vaccine or antiviral is licensed to combat this disease. An obstacle complicating dengue research is the lack of animal challenge models that mimic human disease. Advances in immunocompromised murine infection models resulted in development of lethal DENV-2, DENV-3 and DENV-4 models in AG129 mice, which are deficient in both the IFN-α/β receptor (IFN-α/βR) and the IFN-γ receptor (IFN-γR). These models mimic features of dengue disease in humans. Here, we characterized lethal infection of AG129 mice by DENV-4 strain TVP-376 and found that AG129 mice developed clinical signs of illness and high viral loads in multiple tissues and succumbed 5 days after infection. Moreover, the splenic and hepatic histopathology of TVP-376-infected mice demonstrated the presence of cell activation and destruction of tissue architecture. Furthermore, infected mice had heightened levels of circulating cytokines. Comparison of the virulence phenotypes of DENV-4 strain TVP-376 and DENV-2 strain D2S10 revealed that TVP-376-induced mortality occurred in the absence of both IFN-α/βR and IFN-γR signalling, but not with intact signalling from the IFN-γR, whereas D2S10 required the absence of IFN-α/βR signalling only, indicating that it is more virulent than TVP-376. In conclusion, TVP-376 is lethal in AG129 mice, and this model provides a useful platform to investigate vaccine candidates and antivirals against DENV-4.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000246
2015-10-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/10/3035.html?itemId=/content/journal/jgv/10.1099/jgv.0.000246&mimeType=html&fmt=ahah

References

  1. Aguirre S., Maestre A.M., Pagni S., Patel J.R., Savage T., Gutman D., Maringer K., Bernal-Rubio D., Shabman R.S., other authors. ( 2012;). DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog 8: e1002934 [CrossRef] [PubMed].
    [Google Scholar]
  2. Ashour J., Morrison J., Laurent-Rolle M., Belicha-Villanueva A., Plumlee C.R., Bernal-Rubio D., Williams K.L., Harris E., Fernandez-Sesma A., other authors. ( 2010;). Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 8: 410–421 [CrossRef] [PubMed].
    [Google Scholar]
  3. Atrasheuskaya A., Petzelbauer P., Fredeking T.M., Ignatyev G.. ( 2003;). Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 35: 33–42 [CrossRef] [PubMed].
    [Google Scholar]
  4. Balsitis S.J., Williams K.L., Lachica R., Flores D., Kyle J.L., Mehlhop E., Johnson S., Diamond M.S., Beatty P.R., Harris E.. ( 2010;). Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790 [CrossRef] [PubMed].
    [Google Scholar]
  5. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., Drake J.M., Brownstein J.S., Hoen A.G., other authors. ( 2013;). The global distribution and burden of dengue. Nature 496: 504–507 [CrossRef] [PubMed].
    [Google Scholar]
  6. Bozza F.A., Cruz O.G., Zagne S.M.O., Azeredo E.L., Nogueira R.M.R., Assis E.F., Bozza P.T., Kubelka C.F.. ( 2008;). Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis 8: 86 [CrossRef] [PubMed].
    [Google Scholar]
  7. Chen H.-W., King K., Tu J., Sanchez M., Luster A.D., Shresta S.. ( 2013;). The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus. J Immunol 191: 4194–4201 [CrossRef] [PubMed].
    [Google Scholar]
  8. Fuchs J., Chu H., O'Day P., Pyles R., Bourne N., Das S.C., Milligan G.N., Barrett A.D., Partidos C.D., Osorio J.E.. ( 2014;). Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. Vaccine 32: 6537–6543 [CrossRef] [PubMed].
    [Google Scholar]
  9. Green A.M., Beatty P.R., Hadjilaou A., Harris E.. ( 2014;). Innate immunity to dengue virus infection and subversion of antiviral responses. J Mol Biol 426: 1148–1160 [CrossRef] [PubMed].
    [Google Scholar]
  10. Johnson A.J., Roehrig J.T.. ( 1999;). New mouse model for dengue virus vaccine testing. J Virol 73: 783–786.
    [Google Scholar]
  11. Messina J.P., Brady O.J., Scott T.W., Zou C., Pigott D.M., Duda K.A., Bhatt S., Katzelnick L., Howes R.E., other authors. ( 2014;). Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol 22: 138–146 [CrossRef] [PubMed].
    [Google Scholar]
  12. Milligan G.N., Sarathy V.V., Infante E., Li L., Campbell G.A., Beatty P.R., Harris E., Barrett A.D., Bourne N.. ( 2015;). A dengue virus type 4 model of disseminated lethal infection in AG129 mice. PLoS One 10: e0125476 [CrossRef] [PubMed].
    [Google Scholar]
  13. Mota J., Rico-Hesse R.. ( 2009;). Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 83: 8638–8645 [CrossRef] [PubMed].
    [Google Scholar]
  14. Orozco S., Schmid M.A., Parameswaran P., Lachica R., Henn M.R., Beatty R., Harris E.. ( 2012;). Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol 93: 2152–2157 [CrossRef] [PubMed].
    [Google Scholar]
  15. Perry S.T., Prestwood T.R., Lada S.M., Benedict C.A., Shresta S.. ( 2009;). Cardif-mediated signaling controls the initial innate response to dengue virus in vivo. J Virol 83: 8276–8281 [CrossRef] [PubMed].
    [Google Scholar]
  16. Perry S.T., Buck M.D., Lada S.M., Schindler C., Shresta S.. ( 2011;). STAT2 mediates innate immunity to dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog 7: e1001297 [CrossRef] [PubMed].
    [Google Scholar]
  17. Prestwood T.R., Morar M.M., Zellweger R.M., Miller R., May M.M., Yauch L.E., Lada S.M., Shresta S.. ( 2012;). Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice. J Virol 86: 12561–12570 [CrossRef] [PubMed].
    [Google Scholar]
  18. Rothman A.L.. ( 2011;). Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11: 532–543 [CrossRef] [PubMed].
    [Google Scholar]
  19. Sarathy V.V., White M., Li L., Gorder S.R., Pyles R.B., Campbell G.A., Milligan G.N., Bourne N., Barrett A.D.T.. ( 2015;). A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. J Virol 89: 1254–1266 [CrossRef] [PubMed].
    [Google Scholar]
  20. Shresta S., Kyle J.L., Snider H.M., Basavapatna M., Beatty P.R., Harris E.. ( 2004;). Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78: 2701–2710 [CrossRef] [PubMed].
    [Google Scholar]
  21. Shresta S., Sharar K.L., Prigozhin D.M., Beatty P.R., Harris E.. ( 2006;). Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208–10217 [CrossRef] [PubMed].
    [Google Scholar]
  22. Simmons C.P., Farrar J.J., van Vinh Chau N., Wills B.. ( 2012;). Dengue. N Engl J Med 366: 1423–1432 [CrossRef] [PubMed].
    [Google Scholar]
  23. Srikiatkhachorn A., Green S.. ( 2010;). Markers of dengue disease severity. Curr Top Microbiol Immunol 338: 67–82 [CrossRef].
    [Google Scholar]
  24. Sukupolvi-Petty S., Brien J.D., Austin S.K., Shrestha B., Swayne S., Kahle K., Doranz B.J., Johnson S., Pierson T.C., other authors. ( 2013;). Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol 87: 8826–8842 [CrossRef] [PubMed].
    [Google Scholar]
  25. Tan G.K., Ng J.K.W., Trasti S.L., Schul W., Yip G., Alonso S.. ( 2010;). A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 4: e672 [CrossRef] [PubMed].
    [Google Scholar]
  26. Yauch L.E., Shresta S.. ( 2008;). Mouse models of dengue virus infection and disease. Antiviral Res 80: 87–93 [CrossRef] [PubMed].
    [Google Scholar]
  27. Zellweger R.M., Shresta S.. ( 2014;). Mouse models to study dengue virus immunology and pathogenesis. Front Immunol 5: 151 [CrossRef] [PubMed].
    [Google Scholar]
  28. Zellweger R.M., Prestwood T.R., Shresta S.. ( 2010;). Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7: 128–139 [CrossRef] [PubMed].
    [Google Scholar]
  29. Zompi S., Harris E.. ( 2012;). Animal models of dengue virus infection. Viruses 4: 62–82 [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000246
Loading
/content/journal/jgv/10.1099/jgv.0.000246
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error